Brean Murray Carret & Co. Maintains a 'Buy' on Dendreon (DNDN); MEDCAC Panel Docs Relatively Benign

November 11, 2010 9:20 AM EST Send to a Friend
Get Alerts DNDN Hot Sheet
Price: $4.01 +1.01%

Rating Summary:
    5 Buy, 15 Hold, 12 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 35 | New: 23
Trade DNDN Now!
Brean Murray Carret & Co. maintains a 'Buy' on Dendreon (NASDAQ: DNDN), PT $65.

Brean analyst says, "TheMEDCAC panel briefing documents were released yesterday after the market close, a full week before the panel, due to a leak of the documents earlier yesterday that apparently benefited DNDN's share price. We view the documents as having a focus on on-label vs. off-label yse, and we are comfortable with its contents. We view the docs as removing an overhang on DNDN's share price and believe that the Nov 17th discussion will reinforce that view."

For more ratings news on Dendreon click here and for the rating history of Dendreon click here.

Shares of Dendreon closed at $34.83 yesterday, with a 52 week range of $25.05-$57.67.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments

Related Entities

Brean Murray Carret & Co.

Add Your Comment